Mithril Ii Gp LP Adagio Therapeutics, Inc. Transaction History
Mithril Ii Gp LP
- $14.8 Billion
- Q1 2025
A detailed history of Mithril Ii Gp LP transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Mithril Ii Gp LP holds 11,241,580 shares of ADGI stock, worth $37.2 Million. This represents 46.08% of its overall portfolio holdings.
Number of Shares
11,241,580
Previous 11,241,580
-0.0%
Holding current value
$37.2 Million
Previous $4.98 Billion
36.61%
% of portfolio
46.08%
Previous 30.95%
Shares
1 transactions
Others Institutions Holding ADGI
# of Institutions
83Shares Held
67.4MCall Options Held
31.6KPut Options Held
54.3K-
Lee Ainslie Maverick Capital LTD | Dallas, Tx11MShares$36.3 Million0.71% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.72MShares$32.2 Million1.13% of portfolio
-
M28 Capital Management LP Stamford, CT9.25MShares$30.6 Million32.33% of portfolio
-
Black Rock Inc. New York, NY4.47MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.4MShares$14.6 Million0.0% of portfolio
About Adagio Therapeutics, Inc.
- Ticker ADGI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 108,831,000
- Market Cap $505M
- Description
- Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...